If You Invested in Apollomics Inc. Warrant (APLMW)

Apollomics Inc. (warrants trading under symbol APLMW) is associated with Apollomics Inc. (Nasdaq: APLM), a late-stage, clinical-stage biopharmaceutical company focused on oncology drug development. According to company disclosures and recent filings, Apollomics is dedicated to the discovery and development of oncology therapies that can be combined with other treatment options to harness the immune system and target specific molecular pathways involved in cancer.

Apollomics describes itself as a clinical-stage biopharmaceutical or biotechnology company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers. Public communications highlight a pipeline of product candidates across several programs, with a particular focus on solid tumors such as non-small cell lung cancer and other advanced tumors with specific molecular alterations.

Core therapeutic focus

The company’s lead program is vebreltinib (APL-101), described as a potent, selective and orally bioavailable c-Met inhibitor. Apollomics states that vebreltinib is being developed for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations or dysregulation. The program is in a Phase 2 multicohort clinical trial in the United States and other countries, and Apollomics has referred to this global Phase 2 program as the SPARTA trial in its operational updates.

Company communications explain that vebreltinib targets the HGF/c-MET axis, a pathway involved in tumor growth, proliferation and resistance to certain targeted therapies. Apollomics has reported clinical and preclinical activity of vebreltinib in a variety of tumor settings characterized by MET dysregulation, including non-small cell lung cancer with MET amplification, non-central nervous system solid tumors with MET fusions, and tumors with MET exon 14 skipping mutations.

Pipeline and programs

In addition to vebreltinib, Apollomics has described a broader oncology pipeline. Public updates reference multiple product candidates across several programs, including:

• Vebreltinib (APL-101), a c-Met inhibitor in late-stage clinical development for MET-dysregulated tumors.
• APL-122, an ErbB1/2/4 inhibitor licensed from Edison Oncology Holding Corporation, which has been evaluated in a Phase 1 trial.
• APL-102, an oral small molecule multi-target kinase inhibitor (MTKi) targeting VEGFR, MAPK pathways via B-RAF and C-RAF, and colony stimulating factor 1 receptor, which has been studied in a Phase 1 clinical trial in China.
• Historical work on uproleselan (APL-106), a specific E-selectin antagonist evaluated in combination with chemotherapy in acute myeloid leukemia, including a Phase 3 bridging trial in China.

Company communications indicate that Apollomics has at times prioritized certain programs and wound down others based on clinical data and strategic focus. For example, after a Phase 3 bridging trial of uproleselan in China did not demonstrate favorable benefit, Apollomics reported that it was wrapping up that program and had previously written down the related intangible asset.

Strategic collaborations and regional development

Apollomics has disclosed collaboration and licensing arrangements intended to support regional development and commercialization of its oncology candidates. For vebreltinib, the company has highlighted a collaboration with LaunXP for development and commercialization in Asia (excluding mainland China, Hong Kong and Macau) in combination with an EGFR inhibitor for the treatment of non-small cell lung cancer. Under that agreement, Apollomics is entitled to upfront payments, potential pre-commercial milestone payments and royalties on net product sales, subject to the terms of the agreement. Subsequent filings describe disputes over payment timing and obligations under this collaboration.

Apollomics has also referenced licensing and collaboration relationships with partners in China and Taiwan in connection with vebreltinib and related clinical development and regulatory strategies. Company statements note that a partner in China has received conditional approval from the National Medical Products Administration of China for vebreltinib for multiple indications, while vebreltinib remains under clinical investigation and is not approved for use in other regions.

Corporate and listing information

Apollomics Inc. is organized as a Cayman Islands exempted company and has described itself as California-based in certain news releases, with principal executive offices in Foster City, California, as reflected in its Form 6-K filings. The company’s Class A ordinary shares trade on the Nasdaq Capital Market under the symbol APLM, and its public warrants trade under the symbol APLMW.

Company disclosures document various corporate actions related to its capital structure and Nasdaq listing. These include a 1-for-100 reverse share split of its Class A ordinary shares, after which the shares continued to trade on a split-adjusted basis under the symbol APLM, and confirmation from Nasdaq that the company regained compliance with the minimum bid price requirement. The company has also reported private placement transactions (PIPE financings) that resulted in the issuance of additional Class A ordinary shares to accredited investors.

Governance and recent developments

Recent Form 6-K filings describe changes in Apollomics’ board composition and executive leadership. The company has reported the appointment and resignation of various directors, as well as the appointment of a Chairman of the Board, Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. These filings provide biographical details for new directors and executives, emphasizing experience in biotechnology, venture capital, finance and corporate restructuring.

In August 2025, Apollomics filed a Form 6-K stating that, due to its cash position, it had terminated all U.S. employees and expected to discontinue activities related to the SPARTA clinical trial and had called an extraordinary general meeting to seek shareholder approval to wind up the company. Subsequent filings and news releases describe a PIPE financing, changes in the board and management, and a reversal of the previously announced wind-up plans, with the new leadership indicating an intention to continue operations and advance development of vebreltinib and related programs.

Business risks and financial context

Apollomics’ public financial statements and Form 6-K filings show that the company has incurred significant research and development and administrative expenses and has reported net losses over multiple reporting periods. The company has also disclosed that its liquidity and ability to continue as a going concern are sensitive to the receipt of collaboration payments and financing proceeds. For example, Apollomics has stated that delays or non-payment of agreed upfront fees under its LaunXP collaboration could have a material adverse effect on its liquidity, financial condition and operations.

Because Apollomics remains a clinical-stage biopharmaceutical company, its future prospects depend on the outcomes of clinical trials, regulatory reviews and its ability to secure sufficient funding. The warrants trading under the symbol APLMW are linked to the company’s Class A ordinary shares and are affected by these underlying business and financial factors, as reflected in the company’s reverse share split and corresponding adjustment to the warrant exercise price.